Condition

Advanced Non-Small Cell Lung Cancer clinical trials and research

• 21Clinical trials
• 46Countries

Newest Advanced Non-Small Cell Lung Cancer clinical trials

All recruiting trials (21)

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

  This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07668037

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

• Lorlatinib with local consolidation therapy for ALK-positive advanced non-small cell lung cancer

  This trial will test whether adding local consolidation treatments to lorlatinib helps people with ALK-positive advanced non-small cell lung cancer stay progression-free longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07415005

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

• Ubamatamab with or without REGN7075 for adults with advanced or metastatic non-small cell lung cancer

  This trial will try ubamatamab alone and with REGN7075 in adults with advanced or metastatic non-small cell lung cancer to see if they control the cancer and will try sarilumab to manage immune-related side effects.

  Recruiting at 18 sites Phase 2 Regeneron Pharmaceuticals · Birmingham, Alabama and 17 other locations · NCT07154290

• HS-IT101 Injection for Advanced NSCLC: a one-arm cell therapy approach

  This study tests whether a patient’s own tumor-infiltrating lymphocytes, given after conditioning with chemotherapy, can be safely given to adults with advanced non-small cell lung cancer.

  Recruiting Phase 1 Hangzhou Huasai Biomedicine Co., Ltd. · Guangzhou, Guangdong · NCT07105176

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• SSGJ-707 versus pembrolizumab for advanced non-small cell lung cancer

  This Phase III test will see if SSGJ-707 works as well as or better than pembrolizumab for adults with stage IIIB/IIIC (not suitable for radical therapy) or stage IV non-small cell lung cancer whose tumors have PD-L1 TPS ≥1% and who have ECOG performance status 0–1 and no prior systemic therapy.

  Recruiting Phase 3 Shenyang Sunshine Pharmaceutical Co., LTD. · Shanghai · NCT06980272

• Tepotinib versus standard treatments for advanced MET exon 14–mutated non-small cell lung cancer after prior therapy

  This study will test whether tepotinib works better than standard chemotherapy choices for people with advanced non-small cell lung cancer that has a MET exon 14 mutation and whose disease progressed after at least one prior treatment.

  Recruiting at 29 sites Phase 3 Intergroupe Francophone de Cancerologie Thoracique · Besançon and 28 other locations · NCT06908993

• JSKN016 combination therapy for advanced non-small cell lung cancer

  The study will try combining JSKN016 with chemotherapy or targeted antibodies to see if it helps adults whose non-small cell lung cancer is locally advanced or has spread.

  Recruiting Phase 1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Guangzhou, Guangdong · NCT06868732

• Reduced chemotherapy and immunotherapy for older adults with advanced lung cancer

  This study is testing a lower dose of chemotherapy combined with immunotherapy to see if it's safe and tolerable for older adults over 70 with advanced lung cancer who can’t have curative treatment.

  Recruiting at 2 sites Phase 2 Virginia Commonwealth University · Richmond, Virginia and 1 other locations · NCT06731413

• Combining almonertinib and anlotinib for advanced lung cancer treatment

  This study is testing a new combination of two drugs, almonertinib and anlotinib, to see if it can help people with advanced lung cancer who have certain genetic mutations.

  Recruiting Phase 3 Qianfoshan Hospital · Jinan, Shandong · NCT06043973

• Combining inhaled antibiotics with pembrolizumab for advanced lung cancer

  This study is testing if using inhaled antibiotics along with a cancer drug can help people with advanced lung cancer feel better and improve their treatment results.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05777603

• Combining IBI351 with chemotherapy for advanced lung cancer with KRAS G12C mutation

  This study is testing if a new drug called IBI351 can work better with chemotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Jilin City, Changchun · NCT05504278

• Injectable SHR-A1811 with Pyrotinib or SHR-1316 for advanced lung cancer

  This study is testing if a new injectable treatment called SHR-A1811, used with either Pyrotinib or SHR-1316, can help people with advanced lung cancer that has a specific marker called HER2.

  Recruiting at 2 sites Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT05482568

• First-in-human test of BAY2927088 for advanced NSCLC with EGFR and/or HER2 mutations

  This study tests BAY2927088 to see if it is safe and tolerable in people with advanced NSCLC that carry EGFR or HER2 mutations.

  Recruiting at 3 sites Phase 1/2 Bayer · Gilbert, Arizona and 93 other locations · NCT05099172

• Predicting response to PD-1 immunotherapy in advanced lung cancer patients

  This study is trying to find out if certain markers in tumors can help predict how well advanced lung cancer patients will respond to a specific immunotherapy treatment.

  Recruiting University Hospital, Brest · Brest · NCT04886401

• Treatment for advanced lung cancer with KRAS G12C mutation

  This study is testing a new treatment called adagrasib, alone and with another drug called pembrolizumab, to see if it helps people with advanced lung cancer that has a specific mutation.

  Recruiting at 382 sites Phase 2/3 Mirati Therapeutics Inc. · Goodyear, Arizona and 769 other locations · NCT04613596

• T Cell Receptor Immunotherapy for Metastatic Non-Small Cell Lung Cancer

  This study is testing a new treatment for advanced lung cancer that uses special immune cells from patients' own tumors to see if it can help shrink their cancer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02133196

Related topics

Quick answers

How many Advanced Non-Small Cell Lung Cancer clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 46 countries. The most sites are in China (12 trials), United States (9 trials), France (6 trials), Spain (5 trials), Japan (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 3: 5, Phase 2: 4, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →